Literature DB >> 17693479

Hybrid quantum mechanical/molecular mechanical molecular dynamics simulations of HIV-1 integrase/inhibitor complexes.

Nadtanet Nunthaboot1, Somsak Pianwanit, Vudhichai Parasuk, Jerry O Ebalunode, James M Briggs, Sirirat Kokpol.   

Abstract

Human immunodeficiency virus (HIV)-1 integrase (IN) is an attractive target for development of acquired immunodeficiency syndrome chemotherapy. In this study, conventional and coupled quantum mechanical and molecular mechanical (QM/MM) molecular dynamics (MD) simulations of HIV-1 IN complexed with 5CITEP (IN-5CITEP) were carried out. In addition to differences in the bound position of 5CITEP, significant differences at the two levels of theory were observed in the metal coordination geometry and the areas involving residues 116-119 and 140-166. In the conventional MD simulation, the coordination of Mg(2+) was found to be a near-perfect octahedral geometry whereas a distorted octahedral complex was observed in QM/MM. All of the above reasons lead to a different pattern of protein-ligand salt link formation that was not observed in the classical MD simulation. Furthermore to provide a theoretical understanding of inhibition mechanisms of 5CITEP and its derivative (DKA), hybrid QM/MM MD simulations of the two complexes (IN-5CITEP and IN-DKA) have been performed. The results reveal that areas involving residues 60-68, 116-119, and 140-149 were substantially different among the two systems. The two systems show similar pattern of metal coordination geometry, i.e., a distorted octahedron. In IN-DKA, both OD1 and OD2 of Asp-64 coordinate the Mg(2+) in a monodentate fashion whereas only OD1 is chelated to the metal as observed in IN-5CITEP. The high potency of DKA as compared to 5CITEP is supported by a strong salt link formed between its carboxylate moiety and the ammonium group of Lys-159. Detailed comparisons between HIV-1 IN complexed with DKA and with 5CITEP provide information about ligand structure effects on protein-ligand interactions in particular with the Lys-159. This is useful for the design of new selective HIV-1 IN inhibitors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17693479      PMCID: PMC2072063          DOI: 10.1529/biophysj.107.108464

Source DB:  PubMed          Journal:  Biophys J        ISSN: 0006-3495            Impact factor:   4.033


  42 in total

1.  Discovery of a novel binding trench in HIV integrase.

Authors:  Julie R Schames; Richard H Henchman; Jay S Siegel; Christoph A Sotriffer; Haihong Ni; J Andrew McCammon
Journal:  J Med Chem       Date:  2004-04-08       Impact factor: 7.446

2.  HIV-1 integrase pharmacophore model derived from diverse classes of inhibitors.

Authors:  Gabriela Iurcu Mustata; Alessandro Brigo; James M Briggs
Journal:  Bioorg Med Chem Lett       Date:  2004-03-22       Impact factor: 2.823

3.  A combined QM/MM approach to protein--ligand interactions: polarization effects of the HIV-1 protease on selected high affinity inhibitors.

Authors:  Christian Hensen; Johannes C Hermann; Kwangho Nam; Shuhua Ma; Jiali Gao; Hans-Dieter Höltje
Journal:  J Med Chem       Date:  2004-12-30       Impact factor: 7.446

4.  Comparison of multiple molecular dynamics trajectories calculated for the drug-resistant HIV-1 integrase T66I/M154I catalytic domain.

Authors:  Alessandro Brigo; Keun Woo Lee; Gabriela Iurcu Mustata; James M Briggs
Journal:  Biophys J       Date:  2005-03-11       Impact factor: 4.033

Review 5.  Integrase inhibitors to treat HIV/AIDS.

Authors:  Yves Pommier; Allison A Johnson; Christophe Marchand
Journal:  Nat Rev Drug Discov       Date:  2005-03       Impact factor: 84.694

6.  Active site dynamics and combined quantum mechanics/molecular mechanics (QM/MM) modelling of a HIV-1 reverse transcriptase/DNA/dTTP complex.

Authors:  Thanyada Rungrotmongkol; Adrian J Mulholland; Supa Hannongbua
Journal:  J Mol Graph Model       Date:  2006-09-14       Impact factor: 2.518

7.  Solvent effects on protein motion and protein effects on solvent motion. Dynamics of the active site region of lysozyme.

Authors:  C L Brooks; M Karplus
Journal:  J Mol Biol       Date:  1989-07-05       Impact factor: 5.469

8.  Design and optimization of tricyclic phtalimide analogues as novel inhibitors of HIV-1 integrase.

Authors:  Wim G Verschueren; Inge Dierynck; Katie I E Amssoms; Lili Hu; Paul M J G Boonants; Geert M E Pille; Frits F D Daeyaert; Kurt Hertogs; Dominique L N G Surleraux; Piet B T P Wigerinck
Journal:  J Med Chem       Date:  2005-03-24       Impact factor: 7.446

9.  Diketo acid pharmacophore. 2. Discovery of structurally diverse inhibitors of HIV-1 integrase.

Authors:  Raveendra Dayam; Tino Sanchez; Nouri Neamati
Journal:  J Med Chem       Date:  2005-12-15       Impact factor: 7.446

10.  Beta-diketo acid pharmacophore hypothesis. 1. Discovery of a novel class of HIV-1 integrase inhibitors.

Authors:  Raveendra Dayam; Tino Sanchez; Omoshile Clement; Robert Shoemaker; Shizuko Sei; Nouri Neamati
Journal:  J Med Chem       Date:  2005-01-13       Impact factor: 7.446

View more
  2 in total

1.  Binding modes of diketo-acid inhibitors of HIV-1 integrase: a comparative molecular dynamics simulation study.

Authors:  Meilan Huang; Guy H Grant; W Graham Richards
Journal:  J Mol Graph Model       Date:  2011-04-09       Impact factor: 2.518

Review 2.  Raltegravir: molecular basis of its mechanism of action.

Authors:  Jean-Francois Mouscadet; Luba Tchertanov
Journal:  Eur J Med Res       Date:  2009-11-24       Impact factor: 2.175

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.